The Use of Endothelial Progenitor Cells for the Regeneration of Musculoskeletal and Neural Tissues.
Naosuke KameiKivanc AtesokMitsuo OchiPublished in: Stem cells international (2017)
Endothelial progenitor cells (EPCs) derived from bone marrow and blood can differentiate into endothelial cells and promote neovascularization. In addition, EPCs are a promising cell source for the repair of various types of vascularized tissues and have been used in animal experiments and clinical trials for tissue repair. In this review, we focused on the kinetics of endogenous EPCs during tissue repair and the application of EPCs or stem cell populations containing EPCs for tissue regeneration in musculoskeletal and neural tissues including the bone, skeletal muscle, ligaments, spinal cord, and peripheral nerves. EPCs can be mobilized from bone marrow and recruited to injured tissue to contribute to neovascularization and tissue repair. In addition, EPCs or stem cell populations containing EPCs promote neovascularization and tissue repair through their differentiation to endothelial cells or tissue-specific cells, the upregulation of growth factors, and the induction and activation of endogenous stem cells. Human peripheral blood CD34(+) cells containing EPCs have been used in clinical trials of bone repair. Thus, EPCs are a promising cell source for the treatment of musculoskeletal and neural tissue injury.
Keyphrases
- stem cells
- endothelial cells
- bone marrow
- clinical trial
- peripheral blood
- spinal cord
- skeletal muscle
- cell therapy
- induced apoptosis
- gene expression
- vascular endothelial growth factor
- mesenchymal stem cells
- type diabetes
- randomized controlled trial
- single cell
- oxidative stress
- insulin resistance
- signaling pathway
- adipose tissue
- metabolic syndrome
- poor prognosis
- cell death
- replacement therapy
- combination therapy
- long non coding rna